The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma Meeting Abstract
| Authors: | Kelley, R.; Kudo, M.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y.; Qin, S.; Tai, D.; Lim, H.; Yau, T.; Yong, W.; Cheng, A.; Gasbarrini, A.; de Braud, F.; Bruix, J.; Borad, M.; Standifer, N.; He, P.; Negro, A.; Vlahovic, G.; Sangro, B.; Abou-Alfa, G. |
| Abstract Title: | The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma |
| Meeting Title: | ESMO 22nd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Jul 1-4 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-07-01 |
| Start Page: | S233 |
| End Page: | S234 |
| Language: | English |
| ACCESSION: | WOS:000558722000431 |
| DOI: | 10.1016/j.annonc.2020.04.059 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O-6 -- Source: Wos |
